Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine

Phase 2Recruiting

0 views this week 0 watching⚡ Active

Interest: 42/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Rhabdomyosarcoma, Child

Conditions

Rhabdomyosarcoma, Child

Trial Timeline

Dec 30, 2023 → Jul 31, 2026

NCT ID

NCT05457829

About Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine

Doxorubicin Hydrochloride Liposome+Irinotecan + Temozolomide+Irinotecan+Vincristine is a phase 2 stage product being developed by Sun Pharmaceutical for Rhabdomyosarcoma, Child. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05457829. Target conditions include Rhabdomyosarcoma, Child.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05457829	Phase 2	Recruiting	Dec 30, 2023	Jul 31, 2026	Rhabdomyosarcoma, Child

Competing Products

3 competing products in Rhabdomyosarcoma, Child

See all competitors

Product	Company	Stage	Hype Score
Eribulin mesylate	Eisai	Phase 2	35
Dasatinib	Bristol Myers Squibb	Phase 2	35
Epirubicin Hydrochloride + Ifosfamide + Sorafenib Tosylate	Bayer	Phase 2	32